Glide Technologies Completes Successful Proof-of-Concept Study With Novel Solid Dose Formulation of Teriparatide SDI®

OXFORD, England, April 23, 2015 /PRNewswire/ --

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo^®/Forsteo^®). Based on these results, the company intends to transfer the formulation production process to a contract manufacturing organisation in the coming months, and to advance Glide teriparatide delivered with the company's needle-free solid dose injector (teriparatide SDI®) into clinical trials in 2016.

The pre-clinical study compared the pharmacokinetic profile of the most widely used clinical dose of teriparatide (20 mcg) with that of Glide's solid dose formulation delivered using the company's SDI^®. The results demonstrated that there was no statistical difference between the two profiles (p<0.05). Teriparatide is currently approved for use in the treatment of osteoporosis with 2014 sales in excess of $1.3 billion.

Dr Mark Carnegie-Brown, Glide's CEO, commented: "These results follow positive equivalence data with octreotide SDI^®, and demonstrate the flexibility of the Glide SDI^® platform in delivering therapeutic peptides. We believe that the Glide SDI^® will have particular advantages with self-administered treatments, such as teriparatide and octreotide, and we are expanding our pipeline to encompass additional therapeutic areas where patient-focused products are key, such as diabetes."

About Glide Technologies 

Glide is a development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics.  It has a growing pipeline of products based on its proprietary solid dose injector, the Glide SDI^®, which offers the potential of improved compliance in long-term therapy and enhanced immune responses to vaccines.  Glide's pipeline of solid dose formulations includes octreotide, parathyroid hormone and anthrax and influenza vaccines. Glide is also developing a novel non-invasive diagnostic technology, initially focused on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker.

The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors.  Glide Technologies has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.  For more information please visit http://www.glide-technologies.com.

Contacts
Dr Mark Carnegie-Brown
Chief Executive Officer
Glide Technologies
Tel: +44-(0)1235-577120

Richard Bungay
Chief Financial Officer
Glide Technologies
Tel: +44-(0)1235-577120

Rob Budge
RJB Communications
Tel: +44-(0)1865-760969
Mobile: +44-(0)7710-741241

SOURCE Glide Technologies

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED